Raab & Moskowitz Asset Management LLC Has $3.67 Million Stock Holdings in Merck & Co., Inc. (NYSE:MRK)


Share on StockTwits

Raab & Moskowitz Asset Management LLC boosted its position in shares of Merck & Co., Inc. (NYSE:MRK) by 2.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 47,640 shares of the company’s stock after purchasing an additional 1,148 shares during the period. Merck & Co., Inc. accounts for approximately 1.4% of Raab & Moskowitz Asset Management LLC’s portfolio, making the stock its 18th biggest position. Raab & Moskowitz Asset Management LLC’s holdings in Merck & Co., Inc. were worth $3,672,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Norges Bank bought a new position in Merck & Co., Inc. during the fourth quarter valued at about $2,250,767,000. Nuveen Asset Management LLC raised its holdings in Merck & Co., Inc. by 20.4% during the fourth quarter. Nuveen Asset Management LLC now owns 24,251,965 shares of the company’s stock valued at $1,983,811,000 after buying an additional 4,112,158 shares in the last quarter. Morgan Stanley raised its holdings in Merck & Co., Inc. by 16.7% during the fourth quarter. Morgan Stanley now owns 22,569,366 shares of the company’s stock valued at $1,846,174,000 after buying an additional 3,221,509 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Merck & Co., Inc. by 0.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 18,956,192 shares of the company’s stock worth $1,550,617,000 after purchasing an additional 139,485 shares during the period. Finally, California Public Employees Retirement System increased its stake in shares of Merck & Co., Inc. by 31.6% in the fourth quarter. California Public Employees Retirement System now owns 13,542,412 shares of the company’s stock worth $1,107,769,000 after purchasing an additional 3,252,367 shares during the period. 72.86% of the stock is owned by hedge funds and other institutional investors.

Several equities analysts recently issued reports on MRK shares. SVB Leerink lowered their price target on Merck & Co., Inc. from $103.00 to $102.00 and set an “outperform” rating on the stock in a research note on Friday. Cantor Fitzgerald restated an “overweight” rating on shares of Merck & Co., Inc. in a research report on Friday, February 5th. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Merck & Co., Inc. presently has an average rating of “Buy” and a consensus price target of $97.22.

Shares of Merck & Co., Inc. stock traded up $0.16 during trading on Tuesday, hitting $76.14. 207,340 shares of the stock were exchanged, compared to its average volume of 11,885,203. The stock has a market capitalization of $192.66 billion, a price-to-earnings ratio of 16.81, a price-to-earnings-growth ratio of 1.89 and a beta of 0.43. The company has a fifty day moving average price of $76.83 and a 200-day moving average price of $78.38. Merck & Co., Inc. has a 1-year low of $71.71 and a 1-year high of $87.80. The company has a current ratio of 1.30, a quick ratio of 1.00 and a debt-to-equity ratio of 0.90.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Thursday, April 29th. The company reported $1.40 earnings per share for the quarter, missing the consensus estimate of $1.63 by ($0.23). The firm had revenue of $12.08 billion for the quarter, compared to analyst estimates of $12.71 billion. Merck & Co., Inc. had a return on equity of 53.83% and a net margin of 24.33%. The firm’s revenue for the quarter was up .2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.50 earnings per share. Equities research analysts forecast that Merck & Co., Inc. will post 5.9 EPS for the current fiscal year.

Merck & Co., Inc. Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products.

See Also: What is the Current Ratio?

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.